Hims & Hers Health, Inc. Stock Price

In a nutshell: Hims & Hers’ invests heavily and will reap benefits sooner or later. Every step we see has the long term goal on the background, to be a front door for customers, the delivery channel, the platform.Read more

COMPANY ANALYSIS : Hims & Hers is a telehealth company founded in 2017 with the mission of improving wellness through accessible healthcare. The company operates primarily in the United States, Canada and Europe growing largely through the acquisition of the telehealth platform ZAVA, planning on further international growth.Read more

Summary Platform Play, Not a Pill Company: Hims is building the infrastructure for personalised, direct-to-consumer healthcare across diagnostics, treatment, and prevention, similar to what Amazon did for retail and Spotify for music. Strong Fundamentals with Operating Leverage: The company is growing fast, generating free cash flow, and scaling efficiently, with rising margins, high retention, and zero debt.Read more

🩺 Business Overview Key Metrics Total: -3/17 +1 ✅ Projected Operating Margin: 12.62% +1 ✅ Projected 5-Year Revenue CAGR: 12.64% -2 ❌❌ Last 5-Year ROIC: -18.95% -2 ❌❌ Estimated Cost of Capital: 7.70% (greater than ROIC) -1 ❌ Last 5-Year Shares Outstanding CAGR: +8.43% +2 ✅✅ Projected 5-Year EPS CAGR: 27.08% +0 ⚠️ Projected 5-Year Dividend CAGR: N/A +2 ✅✅ Estimated Debt Rating: Aaa -2 ❌❌ Morningstar Moat: None -2 ❌❌ Morningstar Uncertainty: Very High Hims & Hers Health is a high growth company, being currently on a rapid expansion of its business. This has some advantages like the projected stellar growth of both revenue and EPS but it will also normally represent the dillution of shares to support it and the negative ROIC (lower than the cost of capital) that it should be regularized during the next couple of years.Read more

Catalysts Financial Performance : In 2023 , Hims & Hers reported impressive financial results: Revenue : Reached $872.0 million , reflecting a 65% year-over-year increase. Net Income : Achieved $1.2 million in Q4 2023.Read more

Key Takeaways Regulatory and consumer pressures threaten user growth, pricing power, and margins, especially amid expanding generic competition and industry shifts toward price transparency. Intensifying data privacy laws and escalating competition challenge digital marketing effectiveness, raise compliance and customer acquisition costs, and complicate international expansion and long-term earnings.Read more

Key Takeaways Vertical integration in diagnostics and advanced compounding boosts personalized care, user retention, and unlocks new, durable revenue streams. Investments in AI, data platforms, and global expansion support scalable, automated healthcare delivery, positioning the company for higher margins and sustained earnings growth.Read more

Key Takeaways Diversification into new health categories, innovative tech integration, and international expansion are expected to drive sustained growth, operational efficiency, and increased global market share. Strong user adoption, enhanced personalized offerings, and industry trends toward telehealth position the company for higher recurring revenue and long-term earnings stability.Read more